{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028863","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.992442+00:00","generated_at":"2026-06-11T09:23:12.750583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Qualigen sells FastPack for ~$5M; Q2 loss narrows to $3.5M; FDA OK for QN-302 trial","bullets":["Divested FastPack diagnostics to Chembio (BIOSYNEX) for ~$5M all cash; proceeds for therapeutics pipeline.","FDA cleared IND for QN-302; Phase 1 trial in advanced solid tumors to start H2 2023, targeting 24+ patients in 2024.","Q2 revenue $1.6M (+14% YoY); net loss $3.5M ($0.69/share) vs $4.1M ($1.12) in prior-year quarter.","R&D spend $1.3M (89% on therapeutics); Pan-RAS platform on track for late in vivo candidate by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028863","json":"https://secwatch.observer/filing/0001493152-23-028863.json","markdown":"https://secwatch.observer/filing/0001493152-23-028863.md","text":"https://secwatch.observer/filing/0001493152-23-028863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/0001493152-23-028863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:23:12.750583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc354ef86dbf7377c45584cb722338b81eb9490e","claim":"AIxCrypto Holdings, Inc. reported the quarter ended June 30, 2023 results: revenue approximately $1.6 million.","evidence_excerpt":"Revenues from product sales for the quarter ended June 30, 2023 were approximately $1.6 million compared to approximately $1.4 million for the same period of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/0001493152-23-028863-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"approximately $1.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}